Jeremy M Force, DO

Medical Instructor in the Department of Medicine
Member of the Duke Cancer Institute
Email address jeremy.force@duke.edu

Education and Training

  • Hematology/Oncology Fellowship, Medicine, Duke University School of Medicine, 2014 - 2017
  • Internal Medicine Residency, Indiana University School of Medicine, 2011 - 2014
  • D.O., University of New England, 2011

Publications

Ong, CT, Thomas, SM, Campbell, BM, Greenup, RA, Plichta, JK, Rosenberger, LH, Force, JM, Hyslop, T, Hwang, E-SS, and Fayanju, OM. "A population-based analysis of treatment and outcomes in 2,500 meta plastic breast cancer patients." May 20, 2017.

Full Text

Campbell, BM, Thomas, SM, Ong, CT, Greenup, RA, Plichta, JK, Rosenberger, LH, Force, JM, Hyslop, T, Hwang, E-SS, and Fayanju, OM. "The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database." May 20, 2017.

Full Text

Force, J, Abbott, S, Broadwater, G, Kimmick, G, Westbrook, K, Hwang, S, Kauff, N, Stashko, I, Weinhold, K, Nair, S, Hyslop, T, Blackwell, K, Castellar, E, and Marcom, P. "Abstract P2-04-19: Elucidating the tumor immune microenvironment phenotype in early stage untreated BRCA mutated breast cancer patients." February 15, 2017.

Full Text

Force, J, and Salama, AK. "First-line treatment of metastatic melanoma: role of nivolumab." ImmunoTargets and therapy 6 (January 2017): 1-10. (Review)

PMID
28243579
Full Text

Spiegel, D, Marcom, PK, Peterson, B, Force, J, Howie, L, Palta, M, Blitzblau, RC, and Horton, JK. "Acute Toxicity in Patients With HER2-Positive Breast Cancer Treated With Adjuvant Radiation Therapy and Concurrent Trastuzumab and Pertuzumab." International journal of radiation oncology, biology, physics 96, no. 2S (October 2016): E9-E10.

PMID
27675495
Full Text

Force, JM, Howie, LJ, Abbottt, S, Bentley, RC, Marcom, PK, Kimmick, GG, Westbrook, KE, Parks, M, Topping, DL, Broadwater, G, Blackwell, KL, and Nair, SK. "Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens." May 20, 2016.

Full Text

Howie, L, Marcom, P, Topping, D, Force, J, Emerson, R, Bhavsar, N, Abbott, S, Parks, M, Robins, H, and Blackwell, K. "Abstract P4-14-16: T-cell clonality increases after neoadjuvant treatment with trastuzumab and pertuzumab." February 15, 2016.

Full Text

Force, J, Saxena, R, Schneider, BP, Storniolo, AM, Sledge, GW, Chalasani, N, and Vuppalanchi, R. "Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, no. 3 (January 2016): e9-12.

PMID
24778392
Full Text

Force, J, Rajan, A, Dombi, E, Steinberg, SM, and Giaccone, G. "Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 6, no. 7 (July 2011): 1267-1273.

PMID
21610525
Full Text

Kelly, RJ, Rajan, A, Force, J, Lopez-Chavez, A, Keen, C, Cao, L, Yu, Y, Choyke, P, Turkbey, B, Raffeld, M, Xi, L, Steinberg, SM, Wright, JJ, Kummar, S, Gutierrez, M, and Giaccone, G. "Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib." Clinical cancer research : an official journal of the American Association for Cancer Research 17, no. 5 (March 2011): 1190-1199.

PMID
21224376
Full Text

Pages